Abstract
Parkinson’s Disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease. The majority of cases are sporadic, commonly referred to as idiopathic Parkinson’s disease (IPD). The cardinal clinical features are bradykinesia, rigidity, rest tremor, and postural instability. A flexed posture and the freezing phenomenon are also commonly seen.
Initial descriptions of Parkinson’s disease (PD) and its management following the introduction of levodopa concentrated on the cardinal motor features. Long-term studies and clinicopathological correlation make it clear, however, that this is a disease with diverse effects, also affecting cognition, mood, autonomic function, and the sleep cycle. Patient care has accordingly become increasingly complex. With the exception of deep brain stimulation, diagnostic and therapeutic options have changed little in the past 20 years. Validated biomarkers and disease-modifying therapies are still required. This chapter aims to practically address common clinical issues and update the practitioner on advances in the field.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Pathology, Clinical Features and Natural History of IPD
Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord 2006;21:2042–2051.
Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009 May;8(5):464–74.
de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol 2005;62(1265–1269)
Fahn S. The freezing phenomenon in parkinsonism. Adv Neurol 1995;67:53–63.
Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicentre study of Parkinson’s disease: The inevitability of dementia at 20 years. Mov Disord 2008;23(6):837–844.
Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tnner CM, Trojanowski JQ, Wszolek ZK; DLB/PDD Working group. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68(11):812–819.
Therapeutics in IPD
Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord 2009;15(10):728–741.
Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzi S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J; German Parkinson Study Group, Neurostimulation Section. A randomised Trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006;355(9):896–908
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004;351(24):2498–2508
Fahn S. Parkinson’s Disease: 10 Years of Progress, 1997–2007. Mov Disord 2010; 25, (Suppl. 1):S2–S14
Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinerole or levodopa. Mov Disord 2007;22(16):2409–2417.
Lang AE. When and how should treatment be started in Parkinson disease? Neurology 2009;72(Suppl 2):S39-S43.
Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in do-novo PD: a randomised trial. Neurology 2001;57:1687–1694.
Olanow CW, Goetz CG, Kordower JH, Stoessi AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 2003;54:403–414.
Schapira AH, Obeso J. Timing of treatment initiation in Parkinson’s disease. A need for reappraisal? Ann Neurol 2006;59(559–562)
Genetics of IPD
Healy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol 2008;7(7):583–590
Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denèfle P, Wood NW, Agid Y, Brice A; French Parkinson’s Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson’s Disease. Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med 2000;342:1560–1567
Marder K, Tang MX, Mejia H, Alfaro B, Côté L, Louis E, Groves J, Mayeux R. Risk of Parkinson’s disease among first-degree relatives: A community based study. Neurology 1996;47(1):155–160.
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997;276(5321):2045–2047.
Neuroprotection
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagaline in Parkinson’s disease. N Engl J Med 2009;361(13):1268–1278
Schapira AH. Neuroprotection in Parkinson’s disease. Parkinsonism Relat Disord 2009;15(Suppl. 4):S41-S43.
Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A, Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51(5):604–612
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag London Limited
About this chapter
Cite this chapter
Walsh, R.A., Lynch, T., Fahn, S. (2011). Parkinson’s Disease. In: Hardiman, O., Doherty, C. (eds) Neurodegenerative Disorders. Springer, London. https://doi.org/10.1007/978-1-84996-011-3_5
Download citation
DOI: https://doi.org/10.1007/978-1-84996-011-3_5
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84996-010-6
Online ISBN: 978-1-84996-011-3
eBook Packages: MedicineMedicine (R0)